CervoMed vs Jupiter Neurosciences
CRVO and JUNS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVO and JUNS compare
CervoMed is the larger company, worth 19 times as much as Jupiter Neurosciences ($25.2M against $1.3M).
CervoMed scores higher on the StockData Score (5 against 0 for Jupiter Neurosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVO | JUNS |
|---|---|---|
| Size and price | ||
| Market cap | $25.2M | $1.3M |
| Share price | $1.67 | $1.70 |
| Change, 1 year | −77.0% | −98.3% |
| Change, 5 years | −94.3% | – |
| Beta (5Y) | 3.26 | −0.18 |
| Employees | 15 | 5 |
| StockData Score | ||
| Total score | 5 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 76.2× | – |
| P/B | 1.1× | – |
| Growth | ||
| Revenue growth (TTM) | −95.7% | – |
| Profitability | ||
| Operating margin | −9407% | – |
| Net margin | −9161% | – |
| Return on equity | −108% (better) | −1889% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −36.0× |
| Current ratio | – | 0.66 |
| Altman Z-score | −4.99 (better) | −23.63 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.6% | 2.2% |
| Held by insiders | 36.9% | – |
| Insider net buying, 12 months | $3.0M | – |
| Short interest, % of float | 12.7% | – |
Go deeper
- CRVO stock overview
- CRVO income statement
- CRVO valuation and score
- JUNS stock overview
- JUNS income statement
- JUNS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.